ReviewTrends in endocrinology and metabolism: TEM2016
Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality.
Review in Trends in endocrinology and metabolism: TEM, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Construction of a radiogenomic association map of pancreatic ductal adenocarcinoma.BMC cancer · 2023Article
- Identification of MYEOV-Associated Gene Network as a Potential Therapeutic Target in Pancreatic Cancer.Cancers · 2022Article
- Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand-Addicted Pancreatic Cancer.Molecular cancer therapeutics · 2022Article
- Small Extracellular Vesicles: Functions and Potential Clinical Applications as Cancer Biomarkers.Life (Basel, Switzerland) · 2021Review
- WNT Ligand Dependencies in Pancreatic Cancer.Frontiers in cell and developmental biology · 2021Review
- P21 activated kinase 2 promotes pancreatic cancer growth and metastasis.Oncology letters · 2019Article
- Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer.Oncotarget · 2017Article
- Computational Model Predicts the Effects of Targeting Cellular Metabolism in Pancreatic Cancer.Frontiers in physiology · 2017Article
- Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language.The Yale journal of biology and medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDA) is a devastating malignancy with limited and modest clinical treatments. High-throughput technologies and accurate disease models now provide a comprehensive picture of the diverse molecular signaling pathways and cellular processes governing PDA tumorigenesis. Central among these is oncogenic KRAS, a mediator of cellular plasticity, metabolic reprogramming, and inflammatory and paracrine signaling required for tumor development and maintenance. Biological aggressiveness is further conferred by a highly fibrotic and immunosuppressive PDA microenvironment that also acts as a barrier to effective drug delivery. The regulation of these mechanisms and their implications for early cancer detection, chemoprevention and therapy are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.